In this episode, we break down a new 2026 Wharton’s jelly mesenchymal stem cell (MSC) study and explain why cell potency testing may be just as important as the stem cells themselves in determining treatment success.

You’ll learn:

• What the 2026 Scientific Reports study found in patients with steroid-resistant graft-versus-host disease (GvHD)
• Why Wharton’s jelly MSCs are widely used in immune-related conditions
• How potency assays measure the real functional quality of stem cell batches
• Why were higher potency scores linked to significantly better patient outcomes
• How MSC response rates compare across multiple clinical reviews and studies
• What current research still cannot explain about long-term survival outcomes

This episode explores why consistency in cell quality may be the missing link in regenerative medicine. While Wharton’s jelly MSC therapy continues to show strong short-term response rates, the evidence suggests that not all cell batches perform the same, making potency testing a critical step in future clinical use.

Blog Link: New Wharton’s Jelly MSC Study: Why Cell Quality Testing Matters